Status:

COMPLETED

Metformin Treatment in Progressive Multiple Sclerosis

Lead Sponsor:

University of California, Los Angeles

Conditions:

Secondary Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis

Eligibility:

All Genders

30-65 years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Detailed Description

This will be a single site 1:1 randomized, placebo controlled trial of metformin treatment vs matching placebo in 44 men and women with primary progressive multiple sclerosis and secondary multiple sc...

Eligibility Criteria

Inclusion

  • Patient signed informed consent.
  • Age 30-65
  • Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple Sclerosis as defined by the 2017 McDonald Criteria
  • Intent to maintain current MS disease modifying treatment through the trial duration

Exclusion

  • Clinical relapse in prior 12 months
  • New T2 lesion or gadolinium enhancing lesion in prior 12 months
  • Glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment
  • Changes in disease modifying therapy in prior three months
  • Plans to change current disease modifying therapy
  • Contraindication to MRI, inability to tolerate MRI
  • Use of metformin for any other indication
  • Renal dysfunction (GFR \< 60)
  • Hepatic dysfunction (AST or ALT \> 1.5 x upper limit of normal)
  • B12 deficiency
  • Prior poor reaction to metformin
  • Congestive heart failure
  • Alcohol abuse
  • Metabolic acidosis
  • Females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment
  • Concomitant use of drugs with drug-drug interactions with metformin
  • Previous adverse effect with metformin treatment

Key Trial Info

Start Date :

April 26 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 30 2025

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT05349474

Start Date

April 26 2022

End Date

May 30 2025

Last Update

July 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, Los Angeles

Los Angeles, California, United States, 90095